Over the past 25 years, considerable progress has been made in terms of elucidating the
regulatory and signaling mechanisms underlying the control of skeletal muscle mass by …

Muscle wasting disease indications are among the most debilitating and often deadly
noncommunicable disease states. As a comorbidity, muscle wasting is associated with …

The age-related loss of skeletal muscle (sarcopenia) is a major health concern as it is
associated with physical disability, metabolic impairments, and increased mortality. The …

Myostatin was identified more than 20 years ago as a negative regulator of muscle mass in
mice and cattle. Since then, a wealth of studies have uncovered the potential involvement of …

Muscle wasting is associated with a wide range of catabolic diseases. This debilitating loss
of muscle mass and functional capacity reduces the quality of life and increases the risks of …

The progressive loss of skeletal muscle mass, strength and/or function with advancing age,
termed sarcopenia, poses a major threat to independence and quality of life. Therefore …

Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is
highly expressed in skeletal muscle, was first described in 1997. It has been known that loss …

Myostatin is a member of the transforming growth factor (TGF)-β superfamily. It is expressed
by animal and human skeletal muscle cells where it limits muscle growth and promotes …

Since the discovery of myostatin (MSTN; also known as GDF-8) as a critical regulator of
skeletal muscle mass in 1997, there has been an extensive effort directed at understanding …

Background Loss of skeletal muscle mass and function in humans is associated with
significant morbidity and mortality. The role of myostatin as a key negative regulator of …